Author | Study | Country | Year | Study design | N | Treatment arms | Primary end point |
---|---|---|---|---|---|---|---|
Marèchal R | EudraCT | Belgium | 2011 | Randomized phase II | 57 | (Exp arm): FOLFOX × 2 → CRT (5 FU) → Sx (Control): CRT (5 FU) → Sx | pCR |
Fernandez-Martos C | GCR-3 | Spain | 2015 | Randomized phase II | 108 | (Exp arm): CAPOX × 4 → CRT (CAPOX) → Sx (Control): CRT (CAPOX) → Sx → CAPOX | pCR |
Bujko K | POLISH II | Poland | 2016 | Randomized phase III | 515 | (Exp arm): SCRT → FOLFOX × 2 → Sx (Control): CRT (FOLFOX × 3) → Sx | R0 resection rate |
Moore J | WAIT | Australia | 2017 | Randomized phase II | 49 | (Exp arm): CRT (5FU) → 5 FU × 3 → Sx (Control): CRT (5FU) → Sx | pCR |
Kim SY | KCSG CO 14-03 | Korea | 2018 | Randomized phase II | 108 | (Exp arm): CRT (capecitabine) → CAPOX × 2 → Sx (Control): CRT (capecitabine) → Sx | Downstaging rate |
Deng Y | FOWARC | China | 2019 | Randomized phase III | 495 | (Exp arm): mFOLFOX6 + CRT (5FU) → Sx → 5FU × 7 (Exp arm): mFOLFOX6 × 4–6 → Sx → mFOLFOX6 × 6–8 (Control): CRT (5FU) → Sx → 5FU × 7 | 3-yr DFS |
Bahadoer RR | RAPIDO | Netherlands | 2020 | Randomized phase III | 912 | (Exp arm): SCRT → CAPOX × 6/FOLFOX × 9 → Sx (Control): CRT (capecitabine) → Sx → CAPOX × 6/FOLFOX4 × 12 | DrTF |
Conroy T | PRODIGE-23 | France | 2021 | Randomized phase III | 461 | (Exp arm): FOLFIRINOX × 6 → CRT (capecitabine) → Sx → FOLFOX × 6 (Control): CRT (capecitabine) → Sx → FOLFOX × 12 | 3-yr DFS |